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Abstract
Background: The activation of the aspartate-specific cysteinyl protease, Caspase-6, is proposed as an early pathogenic
event of Alzheimer disease (AD) and Huntington’s disease. Caspase-6 inhibitors could be useful against these
neurodegenerative diseases but most Caspase-6 inhibitors have been exclusively studied in vitro or show
acute liver toxicity in humans. Here, we assessed vinyl sulfone small molecule peptide caspase inhibitors for
potential use in vivo.
Methods: The IC50 of NWL vinyl sulfone small molecule caspase inhibitors were determined on Caspase-1 to
10, and Caspase-6-transfected human colon carcinoma HCT116 cells. Inhibition of Caspase-6-mediated axonal
degeneration was assessed in serum-deprived or amyloid precursor protein-transfected primary human CNS
neurons. Cellular toxicity was measured by phase contrast microscopy, mitochondrial and lactate dehydrogenase
colorimetric activity assays, or flow cytometry. Caspase inhibition was measured by fluorogenic activity assays,
fluorescence microscopy, and western blot analyses. The effect of inhibitors on age-dependent cognitive
deficits in Caspase-6 transgenic mice was assessed by the novel object recognition task. Liquid chromatography
coupled to tandem mass spectrometry assessed the blood-brain barrier permeability of inhibitors in Caspase-6 mice.
Results: Vinyl sulfone NWL-117 caspase inhibitor has a higher selectivity against Caspase-6, −4, −8, −9, and −10
whereas NWL-154 has higher selectivity against Caspase-6, −8, and −10. The half-maximal inhibitory concentrations
(IC50) of NWL-117 and NWL-154 is 192 nM and 100 nM against Caspase-6 in vitro, and 4.82 μM and 3.63 μM
in Caspase-6-transfected HCT116 cells, respectively. NWL inhibitors are not toxic to HCT116 cells or to human
primary neurons. NWL-117 and NWL-154 inhibit serum deprivation-induced Caspase-6 activity and prevent
amyloid precursor protein-mediated neurite degeneration in human primary CNS neurons. NWL-117 crosses
the blood brain barrier and reverses age-dependent episodic memory deficits in Caspase-6 mice.
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Conclusions: NWL peptidic vinyl methyl sulfone inhibitors are potent, non-toxic, blood-brain barrier permeable, and
irreversible caspase inhibitors with neuroprotective effects in HCT116 cells, in primary human CNS neurons, and in
Caspase-6 mice. These results highlight the therapeutic potential of vinyl sulfone inhibitors as caspase inhibitors against
neurodegenerative diseases and sanction additional work to improve their selectivity against different caspases.
Keywords: Alzheimer disease, Caspases, Caspase-6, Axonal degeneration, Peptide inhibitors, Primary human neurons,
Caspase-6 transgenic mice, Vinyl sulfone inhibitors
Background
Alzheimer disease (AD) is a neurodegenerative condition
characterized by cognitive impairments leading to demen-
tia with no disease-modifying treatments. Pathologically,
AD is defined by an accumulation of extracellular plaques
containing mostly amyloid-beta peptide (Aβ) and intracel-
lular neurofibrillary tangles (NFT) composed of a hyper-
phosphorylated form of the microtubule-associated protein
Tau. Clinical trials targeting Aβ plaques have been unsuc-
cessful in restoring cognitive function [1], while trials on
disaggregating NFTs are currently ongoing [2]. The results
from the current clinical trials suggest that therapeutic
intervention against AD could be improved by targeting
earlier pathogenic events.
One emerging potential disease-modifying therapeutic
target is Caspase-6 (Casp6), a cysteinyl protease that
cleaves protein substrates specifically after an aspartic
acid residue [3]. Casp6, but not Casp3 or Casp7, is acti-
vated in neurites interspersing Aβ plaques, NFTs, and
neuropil threads of familial and sporadic AD brains [4–6].
In brains from some aged non-cognitively impaired indi-
viduals, Casp6 activity levels correlates negatively with epi-
sodic and semantic memory performance [7], two types of
memory first affected in AD. Tau-cleaved by Casp6
(TauΔCasp6) levels in post-mortem cerebrospinal fluid
correlate inversely with episodic, semantic, and working
memory performance [8]. Overexpression of human
Casp6 in the CA1 region of mice hippocampi results in
age-dependent episodic and spatial memory loss [9].
These findings suggest that early Casp6 activation in the
hippocampus of aged pre-symptomatic individuals leads
to cognitive impairment.
When activated, Casp6 can impair the microtubule
network within neuronal axons and lead to degener-
ation. Casp6 cleaves the C-terminus of several neuronal
cytoskeletal or associated proteins including Tau and α-
tubulin [4, 10]. In human CNS neuron cultures, overex-
pression of wild type amyloid precursor protein (APPWT),
a condition associated with familial AD [11], results in
Casp6-dependent, but Aβ-independent, neuritic degener-
ation [12]. Therefore, inhibiting Casp6 activity could pre-
vent axonal degeneration.
Caspases play an important role in other neurode-
generative conditions. Casp6 is associated with motor
impairment in the Huntington mouse model [13–18].
Casp6-dependent tubulin fragmentation is associated
with neuritic degeneration in mouse sympathetic, reti-
nocollicular, dorsal root ganglion sensory, commis-
sural, and motor neurons following nerve growth
factor (NGF)-deprivation [19–21]. Casp6 participates
in axonal degeneration of neurturin-deprived dorsal
root ganglion cells [22], myelin-mediated sympathetic
and septal cholinergic neurons [23], ischemic neurons
[24, 25], and retinal ganglion cells in models of optic
nerve injury in rodents [26]. In these conditions, Casp6
is activated in the presence of other caspases, including
Casp9 and Casp3. Similarly, human neonatal, infant,
and adult hypoxic-ischemic brain injury results in in-
creased levels of active Casp6, active Casp3, and tubu-
lin cleaved by Casp6/3 (TubΔCasp6/3) [4, 27].
Natural caspase inhibitors either do not inhibit Casp6 or
are non-selective. Viral proteins p35 and CrmA inhibit sev-
eral caspases [28, 29]. The mammalian inhibitors of apop-
tosis proteins (IAP) do not inhibit Casp6 [30, 31]. There are
two natural Casp6 protein inhibitors: the alternatively
spliced Casp6β isoform, which only prevents Casp6 activa-
tion and the caspase inhibitory factor (CIF), which is react-
ive against other caspases [32, 33]. Many competitive small
molecule Casp6 inhibitors have been developed but most
have not been tested for cellular toxicity, blood brain bar-
rier permeability and in vivo inhibition. Aza-peptides spe-
cifically inhibit caspases and not other cysteine proteases
[34]. Casp6 specificity is improved with sulfonamide isatin
Michael acceptors [35]. Aldehyde or fluoromethyl ketones
(fmk)-conjugated peptides obtained from positional scan-
ning libraries or natural AP-2α and Lamin A Casp6 sub-
strates have been used as Casp6 inhibitors [18, 36–41]. The
commercially available Casp6 inhibitor benzyloxycarbonyl-
Val-Glu-Ile-Asp-fmk (Z-VEID-fmk) is toxic to mammals
because the fmk moiety can be metabolized into fluoroci-
trate, an inhibitor of aconitase that depletes tricarboxylic
acid cycle intermediates [42]. Nevertheless, a Huntington-
based peptide inhibitor conjugated to TAT to enhance
membrane permeability and delivered to the brain with an
osmotic pump protects against behavioral and motor defi-
cits in a mutant Huntingtin mouse model [18].
New World Laboratories Inc. (NWL) has developed
novel peptidomimetic irreversible small molecule inhibitors
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that retain Casp6’s Z-VEID preferred substrate, but have a
methyl vinyl sulfone chemical warhead which 1) is selective
for cysteinyl proteases, 2) is unreactive with circulating
thiols or non-active site cysteines, 3) forms a hydrogen
bond with the active site histidine [43], and (4) is safe in
rats, dogs, and primates [44]. Here, we describe a non-toxic
and blood-brain permeable NWL caspase inhibitor that
prevents axonal degeneration of primary human neurons,
and reverses Casp6-dependent episodic memory impair-
ment in mice. These findings highlight vinyl sulfones as
viable caspase inhibitors for pre-clinical studies.
Methods
DNA constructs
The mammalian constructs encoding human Casp6p20p10
in the pCep4β vector (Thermo Fisher Scientific, Waltham,
MA, USA) [45], and enhanced green flurorescent protein
(EGFP) or EGFP and amyloid precursor protein (APPWT)
in the double promoter-containing pBudCE4.1 vector
(Thermo Fisher Scientific, Waltham, MA, USA) [12] were
previously cloned in our laboratory. A synthetic Escherichia
coli codon-optimized gene (GenScript, Piscataway, NJ,
USA) coding for human Casp6 large subunit (amino acids
24-179, flanked by start (ATG) and stop (TAA) codons)
and small subunit (amino acids 194-293, preceded by a
start codon), separated by GAATTCAATAATTTTGTT
TAACTTTAAGAAGGAGATATACAT containing an in-
ternal ribosome binding site (underlined), was ligated into
the XbaI/XhoI sites of the pET23b(+)-Casp6-His plasmid
(a kind gift from Dr. Guy Salvesen, Sanford Burnham Pre-
bys Medical Discovery Institute, CA, USA), under the con-
trol of a single T7 promoter. All plasmids were sequenced
by the Sanger method (McGill University and Genome
Quebec Innovation Center, Montreal, Quebec, CA).
Recombinant Casp6 Expression and purification:
Casp6 was expressed from the pET23b(+)-Casp6-His
plasmid in E. coli BL21(DE3)pLysS strain (Promega,
Fitchburg, WI, USA) at 37 °C in 2xYT medium (16 g/l
tryptone, 10 g/l yeast extract, 5 g/l NaCl) supplemented
with 0.1 mg/ml ampicillin and 0.034 mg/ml chloram-
phenicol under vigorous shaking according to [46].
Casp6 expression was induced with 50 μM isopropyl β-
D-1-thiogalactopyranoside (IPTG) when cell cultures
reached OD595 nm of 0.6 and cells cultured at 22 °C for
16 h under vigorous shaking. Cells were harvested by
centrifugation, resuspended in buffer A (50 mM Tris
pH 8.5, 300 mM NaCl, 5% glycerol, 2 mM imidazole),
and lysed by sonicating on ice with a Vibra-Cell ultra-
sonic processor (Sonics and Materials, Newtown, CT,
USA) for 2 min at 50% duty with output control set to
four. The lysate was clarified by centrifugation (30,000 x
g for 30 min at 4 °C) and loaded on Ni Sepharose Fast
Flow 6 medium (GE Healthcare Life Sciences, Baie
D’Urfe, QC, CA) pre-equilibrated with buffer A, washed
with buffer B (50 mM Tris pH 8.5, 500 mM NaCl, 5%
glycerol, 20 mM imidazole), and bound proteins eluted
with a 50-300 mM linear imidazole gradient in buffer A.
Fractions were assessed for recombinant Casp6 purity by
SDS-PAGE and Coomassie blue staining. Fractions
containing pure Casp6 were pooled together, dialyzed
against storage buffer (20 mM Tris pH 8.5, 200 mM
NaCl, 10 mM DTT, 5% glycerol), concentrated by dialysis
against polyethylene glycol (PEG) 20,000 (Sigma-Aldrich,
Oakville, ON, CA), and stored at -80 °C in small aliquots.
Protein concentration was measured using Quick Start
Bradford 1x Dye Reagent (Bio-Rad Laboratories, Hercules,
CA, USA). Active site titration assay: The concentration
of Casp6 active sites was determined by active site
titration assay using Z-VAD-fmk (N-benzyloxycarbonyl-
Val-Ala-Asp-(O-methyl)-fluoromethylketone, MP Biomedi-
cals, Santa Ana, CA, USA) inhibitor [46]. Casp6 (398 nM)
was incubated in SB with 0 to 1.25 μM Z-VAD-fmk for 2 h
at room temperature in a final volume of 10 μl, diluted 20-
fold with SB, and 25 μl of aliquots transferred to a black
clear bottom 96-well microplate (Costar, Corning, NY,
USA). Casp6 VEIDase activity (see below) was plotted as a
function of Z-VAD-fmk concentration; the intersection at
the X-axis in the linear region of the curve indicates the
concentration of active sites of Casp6.
Cell cultures and NWL inhibitor treatments
HCT116: Human colon carcinoma (HCT116) cells
(ATCC, Manassas, VA, USA) were cultured in McCoy’s
5A modified media (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% fetal bovine serum
(Thermo Fisher Scientific, Waltham, MA, USA) and
transfected with 1 μg of pCep4βCasp6p20p10 mixed with
8 μg of polyethyleneimine (Polysciences Inc., Warrington,
PA, USA) [47]. Protein expression was allowed for 24 h
before treating with vehicle (PBS), 100 μM NWL-117, or
100 μM NWL-154 for 2 h. For NWL inhibitor kinetic ex-
periments, 100 μM of NWL-117 or NWL-154 was added
at 120, 90, 60, 30, 15, or 0 min before harvest. For the ex-
tended time course from 2 to 48 h, NWL inhibitors were
dissolved in PEG400 (Sigma-Aldrich, Oakville, ON, CA)
(50% v/v), anhydrous ethanol (20% v/v), and 154 mM
NaCl (BioShop Canada Inc, Burlington, Ontario, CA)
(30% v/v)). For recovery time course experiments, after
the initial treatment with 100 μM of NWL-117 or −154
for 2 h, the media was replaced with fresh media for 120,
90, 60, 30, 15, or 0 min before harvest. Primary Human
CNS neurons: Cortical tissues were obtained from the
Birth Defects Research Laboratory (BDRL, University of
Washington, Seattle, USA) in accordance with NIH ethical
guidelines approved by McGill University’s institutional
review board and primary neurons cultured as previously
described [48]. Primary human neurons were seeded on
poly-L-lysine-coated (5 μg/mL) 6-well plates or glass
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coverslips coated with poly-L-lysine and laminin (5 μg/
mL) (Sigma-Aldrich, Oakville, ON, CA) at a density of
3x106 cells/mL. Primary human neurons were pre-treated
with 0.1 μM epoxomicin (Enzo LifeSciences, Farmingdale,
NY, USA) and 100 μM NWL-117, 100 μM NWL-154, or
vehicle (PBS) for 2 h, and serum-deprived for 2 h in the
presence of epoxomicin and vehicle (PBS), 100 μM NWL-
117, or 100 μM NWL-154 before harvesting or measuring
caspase activity with FLICA, as described below.
Casp6 activity assays
Recombinant or extracted cellular Casp6 activity: Casp6
activity was assessed by in vitro fluorogenic assays using
Ac-Val-Glu-Ile-Asp-(7-Amino-4-trifluoromethylcouramin)
(Ac-VEID-AFC: Enzo LifeSciences, NY, USA) as the Casp6
substrate. The activity was measured in Stennicke’s buffer
(SB) (20 mM piperazine-N, N-bis (2-ethanesulfonic acid)
(PIPES: BioShop Canada Inc, Burlington, Ontario, CA)
pH 7.2, 30 mM NaCl, 1 mM ethylenediaminetetraacetic
acid (EDTA), 0.1% 3-[(3-cholamidopropyl)-dimethylammo-
nio]-2-hydroxy-1-propanesulfonic acid (CHAPS), 10% su-
crose) [49]. The reaction mix consisted of either 20 nM
RCasp6 or 20–30 μg cellular protein extracts, SB, 10 mM
DTT, 10 μM VEID-AFC substrate and deionized water.
The activity was measured in a black clear bottom 96-well
plate (Costar, Corning, NY, USA) at 50 μL/well in triplicate
at 37 °C in the Synergy H4 plate reader (BioTek) at excita-
tion 380 nm and emission 505 nm every two minutes for
100 min. Fluorescence units were converted to the moles
of AFC released based on a standard curve of 0–625 pico-
moles of free AFC. Cleavage rates were calculated from the
linear phase of the assay. The activity is considered on a
percentage scale where no inhibitor present is equated to
100% activity of the enzyme. Cellular Casp6 activity assay
by FLICA: Active Casp6 was labeled within primary human
neurons using the fluorescent inhibitor of Casp6 (FLICA)
(FAM-VEID-fmk, ImmunoChemistry, Bloomington, MN,
USA) following the manufacturer’s protocol. Briefly, FLICA
reagent and Hoechst 33342 were added to a black clear
bottom 96-well plate containing 100,000 of the treated-
primary human neurons for 2 h at 37 °C in 5% CO2. The
cells were rinsed twice with wash buffer and fresh media
was added to the cells. The fluorescence of FAM-VEID-
fmk was measured at 490 nm excitation and 520 nm emis-
sion with bandwidth reduced to 8 nm in the Synergy H4
plate reader (BioTek). The Hoechst signal was measured
by excitation at 360 nm and emission at 485 nm.
IC50 determination of NWL inhibitors on recombinant
proteins or in cells
The half-maximal inhibitory concentrations (IC50) for
NWL inhibitors (Patent publication # WO/2009/140765,
WO/2010/133000, and WO/2012/140500) was deter-
mined by incubating 0 to 20 μM NWL-117 and NWL-
154 with 20 nM of active site-titrated Casp6 in SB at room
temperature for 5 minutes. Then, 10 μM Ac-VEID-AFC
was added and fluorescence measured for 20 min at 37 °C
as described above. New World Laboratories performed
the IC50 determination for NWL inhibitors dissolved in di-
methyl sulfoxide (DMSO) against recombinant Casp1-10
using the Caspase Inhibitor Drug Screening Kits (BioVision,
San Francisco, CA) following the manufacturer’s instruc-
tions and the preferred substrates for the caspases (Cas-
pase-1: WAD-AFC, Caspase-2: VDVAD-AFC, Caspase-3:
DEVD-AFC, Caspase-4: LEVD-AFC, Caspase-5: WEHD-
AFC, Casp6:VEID-AFC, Caspase-7: DEVD-AFC, Caspase-
8: IETD-AFC, Caspase-9: LEHD-AFC, Caspase-10:
AEVD-AFC). In transfected HCT116 cells, 0 to 100 μM
NWL inhibitors were added in the culture media and left
on the cells for 2 h. Cells were washed once with 1 mL
ice-cold PBS, incubated on ice for 5 min with 200 μL cell
lysis buffer (CLB) (50 mM HEPES, 0.1% CHAPS,
0.1 mM EDTA), and gently scraped off. Protein con-
centrations were determined by Bradford assay (BioRad,
Mississauga, ON, CA) by measuring the absorbance at
595 nm using the BioTek Synergy H4 plate reader.
Caspase-6 activity was measured in 40–60 μg total protein
as described above. The IC50 for recombinant and cellular
caspases were determined using GraphPad Prism 5.0 (La
Jolla, CA, USA) using a log (inhibitor) – response curve
with a Hill slope of −1.
Microscopy analyses
Immunofluorescence on human neuron cultures: Primary
human neurons were pre-treated 2 h and serum-deprived
in the presence of 100 μM NWL-117, 100 μM NWL-154,
or 5 μM Z-VEID-fmk (Biomol, Plymouth meeting, PA,
USA) for 24 h. Following treatment, human neurons were
washed once with warm PBS, fixed for 20 min at room
temperature with 4% paraformaldehyde (Sigma, Oakville,
ON, CA)/4% sucrose (BioRad, Mississauga, ON, CA) for
TubΔCasp6 or 2% formaldehyde (Thermo Fisher Scien-
tific, Waltham, MA, USA)/0.2% glutaraldehyde (Sigma,
Oakville, ON, CA) for pBudEGFP or pBudEGFP/APPWT-
transfected neurons [50], incubated in permeabilization
buffer (0.1% Triton X-100, 0.1 sodium citrate) for 1 min
on ice, washed with PBS, blocked for 20 min at room
temperature with 10% goat serum (Sigma, Oakville, ON,
CA), and incubated with primary antibodies diluted in
10% goat serum in PBS overnight at 4 °C in a humid
chamber. The glass coverslips were washed with PBS,
and incubated with goat anti-rabbit secondary antibody
coupled to Alexa 488 (Molecular Probes, Eugene, OR,
USA) or Cy3 (GE Healthcare Life Sciences, Baie D’Urfe,
QC, CA) and Hoechst 33342 (ImmunoChemistry,
Bloomington, MN, USA) at 1 μg/mL for 2 h at room
temperature. The coverslips were washed with PBS and
rinsed in Milli-Q water before mounting in fluoromount
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(Dako, Burlington, ON, CA). Images were acquired by
fluorescence microscopy and quantified using the ImageJ
software (NIH, Bethesda, MD, USA) for TubΔCasp6 and
manually counted for transfected EGFP(+)-neurons. Time
lapse-imaging by live fluorescence microscopy: Primary hu-
man neurons were transfected with gold beads coated with
pBudEGFP or pBudEGFP/APPWT using a Helios Gene gun
(BioRad, Mississauga, ON, CA) [12]. Briefly, cells were pre-
treated with 100 μM NWL inhibitors or 5 μM Z-VEID-fmk
for 2 h. The media was removed and the neurons were shot
at 100 psi. The media was quickly replaced with the inhibi-
tors present. The plasmid was expressed for 16 h before
setting up the fluorescence microscope (Nikon Eclipse Ti)
to acquire 20 images per condition every hour for 72 h at
37 °C with 5% CO2. The images were analyzed by counting
the total number of neurons (50–100 neurons per condi-
tion per independent experiment), and the number of
beaded, swollen soma, and healthy neurons. In addition,
the time at which cells beaded was noted. Phase contrast
microscopy: HCT116 cells, plated at a density of 1×105
cells/well and human neurons, plated at a density of 6×106
cells/well on poly-L-lysine were treated with PBS, 100 μM
NWL-117, 100 μM NWL-154, or 2 μM staurosporine (Bio-
mol, Plymouth meeting, PA, USA) for 24 h. Images were
acquired with the Nikon Eclipse Ti microscope and the
NIS-Elements (Version 3.10) software.
Cellular toxicity assays
MTT assay: HCT116 cells or primary human neurons
were seeded in 96-well plates at a density of 1x104 and
1x105 cells per well, respectively. The next day, cells and
neurons were treated with vehicle (PBS), or 20, 50, or
100 μM of NWL-117, NWL-154, or 2 μM staurosporine
for 24 or 48 h. The media was replaced with 0.5 μg/ml
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) (Sigma-Aldrich, Oakville, ON, CA) and
the cells were incubated for 4 h at 37 °C in 5% CO2. The
media was removed before dissolving the formazan crys-
tals in 100 μL DMSO while shaking for 30 min. Once
dissolved, the absorbance of each sample was measured
at 560 nm and 670 nm using the Synergy H4 plate
reader from BioTek (Winooski, VT, USA). LDH Assay:
HCT116 cells were seeded in a 6-well plate at a density
of 1×105 cells/well and treated the following day with
100 μM NWL-117 or −154 or equal volumes of vehicle
(PBS) for 24 h. As a positive control, some cells were
lysed for 2 h in 0.9% Triton X-100 (BioShop Canada Inc,
Burlington, Ontario, CA). Media was collected and
stored at −20 °C or assayed right away using the Cytotox
96 kit (Promega, Madison, WI, USA) following the man-
ufacturer’s protocol. Hydrochloric acid (1 N) was added
for 10 min to stop the reaction, which was read at
490 nm (signal) and 520 nm (background) using the
Synergy H4 plate reader from BioTek. Media without
cells were also used to correct the absorbance. SubG1
population analysis: HCT116 cells were seeded in a 6-well
plate at a density of 1x105 cells/well and treated the fol-
lowing day with 100 μM NWL-117, 100 μM NWL-154,
equal volumes of vehicle (PBS), or 2 μM staurosporine for
24 h. The media was recovered and the cells were trypsi-
nized in 0.25% Trypsin-EDTA (Thermo Fisher Scientific,
Waltham, MA, USA). Both the media and the cells were
combined and centrifuged for 5 min at 4 °C and washed
with cold PBS-EDTA (5 mM). Cells were resuspended in
1 mL cold PBS-EDTA (5 mM), fixed by the dropwise
addition of 3 mL of ice cold 100% ethanol and stored at
−20 °C overnight. After centrifugation, the ethanol was re-
moved and the cells were washed with cold PBS-EDTA
(5 mM). Then, 1 mL of staining solution was added
(5 mM PBS-EDTA, 50 μg/mL propidium iodide, 20 μg/
mL RNAse A (Sigma-Aldrich, Oakville, ON, CA)). The
samples were analyzed by flow cytometry using the FACS
Calibur II instrument (BD Biosciences, Mississauga, ON,
Canada). The data were interpreted using the cell cycle
analysis tool in FlowJo Version 10.0, which determined
the DNA content in cells based on propidium iodide
intensity (Ashland, OR, USA).
Western blot analyses
Protein extracts from HCT116 cells and human primary
neurons were subjected to western blotting analyses.
The 10630 (1:10 000) and GN60622 (1:10 000) neoepi-
tope antibodies against the p20 subunit of active Casp6
(Casp6p20) and α-tubulin cleaved by Casp6 (TubΔCasp6)
were generated previously in our laboratory [4, 10, 51].
The β-actin clone AC-15 (1:5 000, Sigma-Aldrich,
Oakville, ON, CA), Casp6 (1:1 000), Synapsin (1:5 000),
full-length α-tubulin (1:1 000, Cell Signalling Technol-
ogy Inc., Danvers, MA, USA), GFAP (1:3 000, Dako,
Burlington, ON, CA), synaptophysin (1:5 000, Sigma,
Oakville, ON, CA), and PSD95 clone K28143 (1:5 000, UC
Davis/NIH NeuroMab Facility) were purchased. All anti-
bodies were diluted in 5% non-fat dry milk. Secondary
anti-mouse (1:5 000, GE Healthcare Life Sciences, Baie
D’Urfe, QC, CA) and anti-rabbit antibodies (1:5 000,
Dako, Burlington, ON, CA) conjugated to horseradish
peroxidase were used to detect immunoreactive proteins
using ECL prime western blotting detection reagent (GE
Healthcare Life Sciences, Baie D’Urfe, QC, CA) and
Kodak BioMax MR film (Kodak, Rochester, NY, USA).
Secondary anti-mouse conjugated to alkaline phosphatase
(Jackson Immunoresearch Laboratories Inc., West Grove,
PA) was developed with nitro-blue tetrazolium (Thermo
Fisher Scientific, Waltham, MA, USA) and 5-bromo-4-
chloro-3-indolylphosphate (Thermo Fisher Scientific,
Waltham, MA, USA) for chromogenic detection of pro-
teins. The western blots were scanned with an HP scanner
and the images were not manipulated except to adjust the
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brightness/contrast and this was done simultaneously to
the entire blot. Quantification was performed with the
ImageJ software (NIH, Bethesda, MD, USA).
NWL caspase inhibitors and Casp6 transgenic mice
Casp6 transgenic mouse model: All animal procedures
followed the Canadian Council on Animal Care guidelines
and were approved by the McGill Animal care committees.
Sixteen to 20 month old C57BL/6 J mice were bred and
aged in the pathogen-free Goodman Cancer Research
Centre Mouse Transgenic Facility at McGill University.
Mice were housed in a temperature-controlled room at
22 °C and were kept on a 12 h light/dark cycle. Food and
water were available at libitum. Casp6 overexpressing
mice (KI/Cre) express Casp6p20p10 under the CAG pro-
moter (CMV immediate early enchancer/chicken β-
actin promoter fusion) in the CA1 pyramidal cell layer
of the hippocampus under the control of calmodulin
kinase IIa (CAMKIIa)-regulated Cre expression [9]. No
obvious toxicity was observed after a one month treat-
ment of NWL-117 on mice (Additional file 1).
NWL treatments
Only males were used and littermates from each geno-
type (wild type (WT)/WT, WT/Cre, & knock-in (KI/
)Cre) were tested together. The experimenter was blind
to genotype and treatment groups. Mice were adminis-
tered 20 mg/kg NWL-117 or physiological saline (0.9%
NaCl) by intraperitoneal injections two times 48 h apart.
Injection volumes did not exceed 150 μL of 10 mg/mL
NWL-117 prepared in physiological saline. Blood brain
barrier permeability of NWL-117 caspase inhibitor: Briefly,
18–22 month old Casp6 mice were anesthetised with
isoflurane, warmed with a heating blanket, and their
physiological vitals (heart rate, body temperature, and res-
piration) monitored. The skin over the mouse’s neck was
shaved, xylocaine applied, and an incision was made along
the midline. Under a surgical microscope, the right carotid
artery was gently separated from surrounding tissue. Two
suture threads were placed at the proximal and distal ends
of the carotid, and a small incision was made along the ca-
rotid wall. A micro-catheter (attached to a 1 ml syringe
controlled by a micropump) was inserted and pushed to
the entrance of the internal carotid artery. The catheter
was secured in place using suture thread. NWL-117
(20 mg/kg) was infused via the micro-catheter using a
pump set at 50 μL/min (total volume between 64 μL and
130 μL). After 5 min, blood was collected by intra-cardiac
puncture, the mouse was perfused through the heart with
ice cold saline for 2–3 min. The brain was removed and
hippocampi were dissected and frozen on dry ice and
stored. Samples were sent to the Biopharmacy platform at
the University of Montreal (Quebec, Canada) for liquid
chromatography and tandem mass spectrometry analysis.
The integrity of the blood-brain barrier was confirmed by
injecting 3% Evan’s blue solution in 20 month old Casp6
mice. Mouse cognitive analysis by novel object recognition:
Mice were handled during 5 min for one week prior to be-
havioral tests. Novel object recognition (NOR) task was
administered in three phases: habituation, familiarization
(pre-exposure), and test phase. For habituation, mice were
placed in the NOR box (80 cm x 80 cm, Stoelting Co,
Wood Dale, IL, USA) for 5 min. After 24 h, the pre-
exposure phase was initiated by allowing the animals to
explore two identical objects inside the NOR box. Then,
following a 2 h gap, mice were re-introduced to the NOR
box which now contained a familiar and a novel object.
The position of the novel object was counterbalanced be-
tween animals to avoid any bias related to a preference in
the location of the new object and the use of potential
confounding spatial cues. The objects were located in the
middle of the NW and SE quadrants of the box, equidis-
tantly from the box corners and from each other. The
mice were placed in the middle of the SW quadrant.
Washing the box and objects with 70% ethanol eliminated
odour cues. The number of times touching each object
was manually recorded, while the total distance, percent
time moving, and number of entries into virtual cells were
recorded using the HVS 2100 automated video tracking
system (HVS Image, Buckingham, UK). Animals whose
exploration was considered insufficient to allow recogni-
tion (<10 s per object) during the familiarization phase
were excluded from analysis. Different object sets were
used in the pre- and post-tests. Immunohistochemistry on
mouse brain slices: Following behavioural analysis, animals
were anaesthetized under isoflurane and perfused intra-
cardially with ice cold saline for 7 min and 4% paraformal-
dehyde for 20 min. Mice brains were removed and stored
in 10% neutral-buffered formalin (Thermo Fischer Scien-
tific, Waltham, MA, USA) for 24 h then dehydrated in
70% ethanol for 24 h or less. Brains were embedded in
paraffin and cut using a vibratome at the histology plat-
form of the Institute for Research on Immunology and
Cancer (U Montreal). Slides containing 4 μm thick sec-
tions of the anterior hippocampus were deparaffinized in
xylene (Thermo Fisher Scientific, Waltham, MA, USA),
and rehydrated before demasking in antigen retrieval
buffer (10 mM Tris, 1 mM EDTA, pH 9; or 10 mM
tri-sodium citrate, pH 6 for synaptophysin) for 20 min at
97 °C in the Pascal Dako Cytomation (Dako, Burlington,
ON, CA). The immunostaining procedure was automated
using the Dako Autostainer Plus slide processor and the
EnVision Flex system (Dako, Burlington, ON, CA). Slides
were treated with peroxidase for 5 min, then rinsed,
blocked with Serum-Free Protein Block (Dako, Burlington,
ON, CA) for 30 min, and incubated with either Iba1 (1: 2
000, Wako, Richmond, VA, USA), TubΔCasp6 (1: 5 000),
or synaptophysin (1: 8 000, Sigma, Oakville, ON, CA)
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antibodies diluted in EnVision Flex Antibody Diluent
(Dako, Burlington, ON, CA) for 30 min. After rinsing,
the mouse brain slices were incubated with secondary
rabbit-horseradish peroxidase antibody (Dako, Burlington,
ON, CA) for 30 min and diaminobenzidine (Dako,
Burlington, ON, CA) for 10 min before counterstain-
ing with hematoxylin (Dako, Burlington, ON, CA).
Slides were scanned using the MIRAX SCAN (Zeiss,
Oberkochen, Germany) and analyzed using the ImageJ
software (NIH, Bethesda, MD, USA) by measuring the
area of positive immunoreactivity over the total area
in square microns.
Statistical analysis
Statistical analysis of data was performed using Graph-
pad Prism 5.0 (La Jolla, CA, USA). The analyses were
done with ANOVA followed by post-hoc analyses as in-
dicated for each test in the figure legends. Alternatively,
a student t-test was done to compare between two sam-
ples as indicated in figure legends. Significance was set
at p < 0.05 for all experiments.
Results
NWL-117 and −154 are potent peptide-based vinyl methyl
sulfone inhibitors of recombinant active Casp6
NWL-117 and NWL-154 are peptide-based inhibitors
flanked by a lipophilic moiety and a vinyl methyl sulfone
chemical warhead (Fig. 1a). NWL-117 and −154 showed
a dose-dependent Casp6 inhibition with half-maximal
inhibitory concentrations (IC50) of 192 nM and 100 nM,
respectively (Fig. 1b). The peptide backbone of NWL in-
hibitors binds to the active site of Casp6, which allows
the vinyl sulfone warhead to hydrogen bond with the
protonated imidazole ring of histidine, while the cata-
lytic cysteine attacks the β-carbon of the vinyl group
(Fig. 1c). The reaction is irreversibly stabilized under
physiological conditions by histidine de-protonation by
the α-carbon of the vinyl group [43]. Thus, peptide-
based vinyl sulfones are potent, irreversible, and com-
petitive Casp6 inhibitors.
NWL inhibitors inhibit recombinant initiator caspases and
Casp6 at sub-micromolar concentrations
NWL inhibitor specificity was tested on recombinant
Casp1 to Casp10 (Table 1). NWL-117 inhibited effector
Casp6, but not Casp3 or −7. NWL-117 inhibited initi-
ator Casp8, Casp9, and Casp10, and inflammatory
Casp4 but not Casp1 and Casp5. NWL-154 inhibited
most strongly Casp6, Casp8 and Casp10, but not
Casp3, Casp7, Casp9, Casp1, Casp4, or Casp5. Neither
compounds showed inhibitory activity on Casp2. Casp6
IC50 in Fig. 1b differs slightly from these results be-
cause the recombinant Casp1-10 were not active site
titrated as done for Casp6 purified in-house. These re-
sults indicate that NWL-117 and NWL-154 are strong
Fig. 1 NWL inhibitors are irreversible peptide vinyl sulfone inhibitors of Casp6. a Chemical structures of NWL-117 and NWL-154 highlighting the
lipophilic moiety, the peptide backbone, and the chemical warhead. b Dose-response curve for NWL-117 (closed circle, IC50 = 192 nM) or NWL-154
(open circle, IC50 = 100 nM) against 20 nM recombinant active site-titrated Casp6. Data represent the mean ± S.D. for three independent experiments.
c Schematic representation of the mechanism for covalent linkage of vinyl sulfone warheads to the catalytic cysteine of Casp6. 1 Peptide (VEID) binds
to the substrate-binding pocket. 2 This interaction allows the sulfone moiety to form a hydrogen bond with the protonated imidazole ring of histidine.
3 The sulfur from the catalytic cysteine performs a nucleophilic attack on the β-carbon of the vinyl group, which triggers a movement of electrons
leading to the protonation of the α-carbon. The result is a covalent link between the vinyl sulfone inhibitor and Casp6
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Casp6 inhibitors although their selectivity requires
improvement.
NWL-117 and −154 are non-toxic and potent inhibitors of
Casp6 activity in Casp6-transfected HCT116 cells
To address NWL inhibitor efficacy in a cellular context,
human colon carcinoma HCT116 cells were treated with
100 μM NWL-117, NWL-154 or staurosporine as a cell
death control for 24 h (Fig. 2a). NWL inhibitor-treated
cells looked morphologically normal. The mitochondrial
reductive potential of cells treated with 20, 50, or
100 μM NWL-117 or −154 for 24 (Fig. 2b) or 48 h
(Fig. 2c) was comparable to vehicle-treated cells. NWL-
treated cells did not release lactase dehydrogenase
(LDH) (Fig. 2d) nor did the cells show increased sub-G1
levels of DNA (Fig. 2e), excluding necrosis and apop-
tosis, respectively. Therefore, unlike staurosporine, NWL
inhibitors are not toxic to HCT116 cells at the tested
concentrations.
Casp6 overexpression in HCT116 increases Casp6 ac-
tivity fivefold (Fig. 2f ), and 100 μM NWL-117 or −154
treatments for 2 h decreased Casp6 activity by 80% (IC50
4.82 μM; r2 = 0.94) and 96% (IC50 3.63 μM; r
2 = 0.91),
respectively (Fig. 2g-h). Functional inhibition of Casp6
activity was confirmed by a substantial decrease in
TubΔCasp6 and a modest reduction of active Casp6 p20
subunit in cells treated with 100 μM NWL inhibitors
(Fig. 2i). These findings suggest a functional inhibition
of Casp6 by NWL inhibitors within HCT116 cells.
NWL inhibitors block Casp6 activity within minutes in
Casp6-transfected HCT116 cells
To assess the kinetics of NWL-117 and −154-mediated
Casp6 inhibition, Casp6-expressing HCT116 cells were
treated with 100 μM NWL-117 or NWL-154 for 15 to
120 min after 24 h of transfection. Within 15 min of
treatment, Casp6 VEIDase activity decreased signifi-
cantly by 88% with NWL-117 and 95% with NWL-154
and the inhibition continued for 2 (Fig. 3a) and 48 h
(Additional file 2: Figure S1). TubΔCasp6 and Casp6p20
levels were decreased within 15 min of treatment
(Fig. 3b, c).
To assess Casp6 activity recovery, transfected cells
were treated with 100 μM NWL-117 or NWL-154 for
2 h and subsequently replaced with fresh media. Casp6
activity rose by 43% ± 5.0 within the first 15 min of
NWL-117 removal and recovered 85% ± 2.5 of the initial
activity after 2 h (Fig. 3d). In contrast, NWL-154 with-
drawal increased by 21% ± 2.2 within 15 min, reaching
30% ± 15 after 2 h. Western blot analysis showed that
the levels of TubΔCasp6 and Casp6p20 (Fig. 3e–f ) were
consistent with the VEIDase activity restoration (Fig. 3d).
Together, these results indicate that the NWL inhibitors
rapidly inhibit Casp6 activity and that this inhibition can
be rapidly washed out in transfected HCT116 cells.
NWL inhibitors are non-toxic and prevent Casp6-
dependent neuritic degeneration in APPWT-transfected
human CNS neurons
Human primary neurons are primary targets for caspase
inhibitors in neurodegenerating brains, and therefore
these were cells of choice to examine the potential tox-
icity and caspase inhibition by these vinyl sulfone cas-
pase inhibitors. Treatment with 100 μM NWL-117 or
NWL-154 for 24 h did not change neuronal morphology
(Fig. 4a), and showed mitochondrial reductive potential
comparable to vehicle-treated neurons at 24 (Fig. 4b) or
48 h (Additional file 2: Figure S2a). These results indi-
cate that neither NWL-117 nor −154 is toxic at concen-
trations up to 100 μM in human neurons.
Casp6 fluorogenic (Fig. 4c) and fluorescent Casp6 in-
hibitor (FLICA)-measured activity (Fig. 4d) and TubΔ-
Casp6 (Fig. 4e) were decreased by both inhibitors in
serum-deprived human neurons, thus supporting the
ability of NWL-117 and −154 to inhibit intraneuronal
Casp6 activity. Co-expression of APPWT and enhanced
green fluorescent protein (EGFP) induced neuritic beading
and somatic swelling after 48 h (Fig. 4f, g), as previously
observed [12]. NWL-117, NWL-154, or 5 μM Z-VEID-
fmk prevented neuritic beading (Fig. 4h). To study this ef-
fect over time, pBudEGFP- (Additional file 2: Figure S3a)
or pBudEGFP/APPWT− transfected neurons treated with ve-
hicle (Fig. 4i) or NWL-117 (Additional file 2: Figure S3b)
were assessed for beading by live fluorescent microscopy
for a 72 h period. The percentage of beaded neurons
increased significantly by 1.52 fold ± 0.07 with APPWT
compared to EGFP-alone (1.00 ± 0.05) and decreased to
0.84 fold ± 0.13, 1.07 fold ± 0.08, 0.97 fold ± 0.14 with
NWL-117, −154, or 5 μM Z-VEID-fmk treatment,
respectively (Fig. 4j). Analyses with time indicate that
the NWL-117-treated neurons have less beading com-
pared to both pBudEGFP-transfected and pBudEGFP/
Table 1 Half-maximal inhibitory concentrations (IC50)
a of NWL-117 and NWL-154 against recombinant Caspase-1 to −10
Cpd No. MWb Caspase-
1 2 3 4 5 6 7 8 9 10
NWL-117 668 2.7 >100 6.96 0.38 19.54 0.60 >100 0.66 0.79 0.13
NWL-154 703 3.85 >100 1.34 1.80 4.19 0.23 >100 0.53 6.40 0.19
aIC50 values are measured in μM
bMolecular weight in g/mol
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APPWT− transfected neurons (Fig. 4k). This protection is at-
tenuated after 24 h because media was not replenished
with the NWL-117 to avoid loosing the settings for the
time-lapse microscopy. Similarly, neuronal soma rounding
was inhibited by NWL-117 (Fig. 4l). Finally, a measure of
neurons with homogeneously distributed EGFP as a meas-
ure of health shows that NWL-117 significantly increases
neuronal survival under these conditions (Fig. 4m) There-
fore, NWL-117 showed stronger neuroprotective effects
than NWL-154 against neuronal beading and rounding in
the APPWT -transfected human neurons.
NWL-117 penetrates the blood-brain barrier and reaches
high nanomolar concentrations in mouse brains
To assess the blood-brain barrier permeability of NWL-
117, 18 month old Casp6-expressing transgenic mice
were injected via the carotid artery. Liquid chromatog-
raphy/tandem mass spectrometry (LC/MS-MS) analyses
Fig. 2 Non-toxic concentrations of NWL-117 and −154 inhibit Casp6 activity in HCT116 cells. a Phase contrast microscope images of HCT116 cells
treated with phosphate-buffered saline, 100 μM NWL inhibitors, or 2 μM staurosporine for 24 h. Scale bar represents 10 μm. b & c MTT absorbance
following treatment with PBS, NWL-117, or NWL-154 at 20, 50, or 100 μM for 24 h (b) or 48 h (c). No statistical differences were found by two-way
ANOVA with Bonferroni post-tests. d Lactate dehydrogenase activity in untreated cells, or treated with PBS, 100 μM NWL inhibitors, or lysed with 0.9%
Triton X-100 for 24 h. e Quantification of the sub-G1 population following cell cycle analysis in PBS, 100 μM NWL inhibitors, or 2 μM staurosporine
treatment for 24 h. f VEIDase activity in pCep4β-transfected (mock) or pCep4β-Casp6p20p10 transfected HCT116 cells. Data represent the
mean ± SEM of five independent experiments. Statistical analysis was performed using an unpaired two-tailed t-test (*** p < 0.01). g Casp6
VEIDase activity in cellular extracts from pCep4β-Casp6p20p10-transfected HCT116 cells treated with PBS, NWL-117 or NWL-154 at 100 μM
for 2 h. h Dose-response curve for NWL-117 (closed circle, IC50 = 4.82 μM) and NWL-154 (open circle, IC50 = 3.63 μM) in pCep4β-Casp6p20p10-transfected
HCT116 cells treated for 2 h. i Western blot analysis of samples from panel f and g for α-tubulin-cleaved by Casp6 (TubΔCasp6), α-tubulin (Tubulin),
active Casp6 p20 subunit (Casp6p20), and β-actin. Casp6 expression was allowed for 24 h before treatment with inhibitors in all transfection
experiments. For panels b-g, data represent the mean of three independent experiments ± SEM and were analyzed by one-way ANOVA (p < 0.0001)
with post hoc Dunnett’s multiple comparison test comparing to vehicle-treated (***denotes p < 0.001) unless specified otherwise
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showed hippocampal concentrations ranging from 67.9
nM to 879 nM, while plasma concentrations ranged
from 3.4 μM to 48 μM, after 5 minutes of injection
(Table 2). The ratio between hippocampal and plasma
concentrations suggested low brain penetrance, although
levels greater than the in vitro IC50 against Casp6 (192
nM) and some initiator caspases (Table 1) were reached.
Variability was expected due to the unpredictable effects
of surgery on old mice. Blood-brain barrier integrity was
confirmed with Evan’s blue. These results demonstrate
the ability of NWL-117 to cross the blood-brain barrier
in mice.
Treatment of human Casp6 knock-in mice with NWL-117
improves their performance in the novel object recognition
(NOR) task
Human Casp6 overexpression in the CA1 region of the
hippocampus results in age-dependent episodic memory
Fig. 3 NWL-117 and −154 rapidly inhibit Casp6 activity in HCT116 cells. a Percent VEIDase activity from cellular protein extracts of Casp6-transfected
HCT116 cells treated with either NWL-117 (closed triangle) or −154 (closed circle) at 100 μM for 0, 15, 30, 60, 90, or 120 min. No statistical significant
differences were obtained between NWL-117 and NWL-154. b & c Western blot analysis of samples from panel (a) of NWL-117 (b) and NWL-154
(c) for α-tubulin-cleaved by Casp6 (TubΔCasp6), α-tubulin (Tubulin), active Casp6 p20 subunit (Casp6p20), and β-actin. d Percent VEIDase activity from
cellular extracts after 2 h of treatment with 100 μM NWL-117 (closed triangle) or −154 (closed circle) in Casp6-transfected HCT116 cells followed by the
removal of the inhibitors for 0, 15, 30, 60, 90, or 120 min. e & f Western blot analysis of samples from panel (d) of NWL-117 (e) and NWL-154 (f) for
α-tubulin-cleaved by Casp6 (TubΔCasp6), α-tubulin (Tubulin), active Casp6 p20 subunit (Casp6p20), and β-actin. For panels (a) & (d), data
represent the mean ± SEM of three independent experiments. Statistical analysis was performed by two-way ANOVA (((compound (p = 0.0010),
time (p < 0.0001), interaction (p = 0.4546)); (compound (p < 0.0001), time (p < 0.0001), interaction (p = 0.0054))), respectively, with Bonferroni post-tests
(*p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 4 Non-toxic concentrations of NWL-117 and −154 inhibit Casp6 activity in primary human neurons. a Micrographs of primary human neurons
treated with PBS vehicle, 100 μM NWL inhibitors, or 2 μM staurosporine for 24 h. Scale bar represents 10 μm. b MTT absorbance following treatment
with PBS, NWL-117, or NWL-154 at 20, 50, or 100 μM or 2 μM staurosporine for 24 h (n= 4, one-way ANOVA (p = 0.0169), Tukey’s multiple comparison test
(*p < 0.05)). c VEIDase activity in neuronal extracts following treatment with PBS, 100 μM NWL-117 (n = 5), or 154 (n = 2) for 2 h (one-way ANOVA
(p < 0.0001)). d Casp6 FLICA assay (one-way ANOVA (p = 0.0041)). e Quantification of the number of TubΔCasp6 beads/nuclei in Additional file 1:
Figure S2b (one-way ANOVA (p = 0.0095)). f–h Fluorescence micrographs following transfections with pBudEGFP (f) or pBudEGFP/APPWT (g) stained for
α-tubulin (Cy3), Hoechst, and quantified (h) (one-way ANOVA (p = 0.0385)). Scale bar represents 100 μm for merge and Hoechst panels, and 50 μm for
EGFP panel. i Live-imaging fluorescence micrographs from 0 to 60 h of a human neuron transfected with pBudEGFP/APPWT and pre-treated with
vehicle. The inset highlights the neurite extending upward. Arrowheads indicate agglomerates of EGFP protein within the axonal membrane
while arrows mark a rounded cell body. Scale bar represents 10 μm. j–m Quantification of panel (i) for overall fold increased beaded neurites (j), fold
increased beaded neurons at specific times (k), overall fold increase swollen neuronal soma (l), or normal EGFP positive neurons (m). For
panels (c–e, h), and (j–k) data represent the mean ± SEM (n ≥ 3), one-way ANOVA (p = 0.0005 for j, p =0.0264 for k, and post hoc tests
were performed with Dunnett’s multiple comparison test (*compares to serum (+) or EGFP-vehicle: *p < 0.05, **p < 0.01, ***p < 0.001; #
compares to serum (−) with vehicle or to EGFP/APPWT-vehicle: # p < 0.05, ## p < 0.01, ### p < 0.001) unless stated otherwise. For panel
(m), log-rank Mantel-Cox test was performed to compare between curves
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impairments measured by NOR [9]. Casp6 KI/Cre mice
were tested following the experimental paradigm shown
in Fig. 5a. Control mice spent more time with the novel
object (70% ± 1.6), while KI/Cre mice did not (47% ± 3.6)
(Fig. 5b) in the pre-test. Total path length (Fig. 5c), the
percentage of time moving (Fig. 5d), and total number
of entries in each part of the arena (Fig. 5e) were equiva-
lent in control and KI/Cre mice indicating comparable
locomotor and exploratory activities. Following two in-
traperitoneal injections, NWL-117-treated control mice
performed equally to saline-treated mice (Fig. 5f ). In
contrast, saline-treated KI/Cre mice remained impaired
(Fig. 5g), whereas NWL-117-treated mice regained nor-
mal NOR performance (Fig. 5h). Injections had no effect
on the locomotor or exploratory activities (Fig. 5i–k).
Hence, age-dependent Casp6-mediated deficits in NOR
can be overcome by an acute treatment with NWL-117.
Casp6 substrates, synaptic proteins, and glial
inflammation markers are unchanged in mice hippocampi
following NWL-117 treatment
Western blot analyses (Fig. 6a) showed that old KI/Cre
mice overexpressed Casp6 but TubΔCasp6 levels remained
below detection, as expected since neurons are likely
degenerated. TubΔCasp6 positive immunohistochemical
staining in the CA1 region (Fig. 6b, c) was slightly higher
in saline KI/Cre mice compared to controls (Fig. 6d).
NWL-117-treatment non-significantly decreased TubΔ-
Casp6 levels threefold in control, but increased non-
significantly in KI/Cre mice. Valosin-containing protein
p97 cleaved by Casp6 (Δp97) (Fig. 6e) was not different in
saline and NWL-117 treatments (Fig. 6f).
Synapsin, synaptophysin, and post-synaptic protein
(PSD95) hippocampal protein levels were unchanged
with NWL-117 treatment (Fig. 6g–i, Additional file 2:
Figure S4). Synaptophysin immunoreactivity in the hippo-
campal CA1 region was slightly higher in saline-treated
control than KI/Cre mice, and unchanged in NWL-117-
treated mice (Fig. 6j–l).
Protein analyses of mouse hippocampi showed a non-
significant reduction in microglial ionized calcium binding
adapter molecule 1 (Iba1) levels in KI/Cre mice, whether
treated or not with NWL-117 (Fig. 6m-o). Astroglial glial
fibrillary acidic protein (GFAP) levels also did not change
with NWL-117 treatment (Fig. 6p-q). Thus, analyses could
not detect changes in synaptic proteins, Casp6 substrates,
or inflammatory markers that account for the behavioral
improvement seen in NWL-117-treated KI/Cre mice.
Discussion
Our study demonstrates that NWL inhibitors are 1)
non-toxic, but non-selective, strong Casp6 inhibitors in
vitro, in colon cancer cells, and in primary CNS human
neurons, 2) protective against Casp6-mediated neuritic
degeneration in serum-deprived or APPWT expressing
human neurons, 3) blood-brain barrier permeable, and
4) reversing episodic memory impairments in transgenic
Casp6 mice.
There are several advantages to these vinyl sulfone in-
hibitors. NWL-117 and NWL-154 are potent, non-toxic,
but non-selective Casp6 inhibitors. Both NWL-117 and
NWL-154 inhibited 1) recombinant Casp6 activity (IC50
= 192 nM and 100 nM, respectively), 2) Casp6 activity in
Casp6-transfected HCT116 cells (IC50 = 4.82 μM and
3.63 μM, respectively), and 3) Casp6 activity in serum-
deprived human neurons. In contrast to Z-VEID-fmk
[42], vinyl sulfone inhibitors remain intact after target
engagement [43], and are not toxic to mammals [44].
Similarly, NWL vinyl sulfone inhibitors do not cause cel-
lular toxicity measured by mitochondrial activity, cell
morphology, LDH release, or sub-G1 populations, or
any gross physiological or anatomical changes in vivo
(supplementary document: pathology report). Further-
more, NWL inhibitors non-covalently interact with the
substrate-binding pocket of Casp6 and effectively block
other substrates from entering the active site. In
addition, by bringing the weak vinyl sulfone electrophilic
warhead, near the catalytic histidine and cysteine resi-
dues of Casp6, Casp6 enzymatic activity is irreversibly
blocked. Compared to reversible inhibitors, irreversible
inhibitors can achieve higher potency by completely
inhibiting their target and require less frequent and
lower doses resulting in higher safety profiles [52].
Therefore, the potential that NWL vinyl sulfone inhibi-
tors could be used in humans is high. On the other
hand, as with other active-site directed Casp6 inhibitors
[18, 34–37, 41, 53, 54], NWL inhibitors remain non-
selective for Casp6 since they inhibit many other cas-
pases. Reducing the concentration of NWL inhibitors
can increase selectivity, but significant enhancements in
potency and specificity are still required before these in-
hibitors reach clinical trials. To overcome this limitation,
the unique inactive conformation of Casp6 was targeted
by others [55]. The peptide inhibitor, pep419, targets
and stabilizes the tetrameric inactive form of Casp6 in a
pH-dependent non-competitive manner in vitro and in
Table 2 NWL-117 levels in mice hippocampi and plasma following
carotid artery injectionsa
Animal # Hippocampus Plasma Ratiob
1 193 48521 0.004
2 816 3416 0.239
3 67.9 8998 0.008
4 356 7408 0.048
5 879 25425 0.035
aConcentrations are reported in nM
bRatio of [hippocampal]/[plasma]
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Fig. 5 (See legend on next page.)
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cells [56]. Similarly, non-competitive ligands that stabilize
the L2 loop of Casp6, which normally rearranges during
activation [57], and a potent uncompetitive inhibitor tar-
geting the caspase-substrate interface [58], in vitro, are
effective Casp6 inhibitors. Through these innovative
mechanisms, highly specific inhibitors have emerged, yet
remain to be tested for toxicity and efficiency in cells and
in mice. Nevertheless, active site inhibitors can be chem-
ically modified to reach exquisite selectivity against spe-
cific caspases [59].
The selectivity of VEID is controversial but it remains
the best candidate for targeting the active site of Casp6.
The study by McStay et al. [60] does suggest that VEID
can be cleaved by recombinant Caspase-3 or by
Caspase-3 in extracts from Jurkat cells undergoing in-
trinsic apoptosis after the addition of cytochrome c and
ATP, which activates the apoptosome pathway. However,
other groups have shown that Casp6 is better at cleaving
VEID than Caspase-3 [61, 62]. In fact, the Michaelis-
Menten constant (Km) for VEID is 8-fold lower for re-
combinant Casp6 (30 μm) than it is for Caspase-3
(250 μm) [37]. This suggests that VEID binds the active
site of Casp6 with greater affinity than that of Caspase-3.
Similarly, the IC50 and the inhibitory constant (Ki) of z-
VEID-CHO (aldehyde) are 2-fold smaller for Casp6 than
they are for Caspase-3 [58]. These data suggest that
VEID is a preferred substrate of Casp6, although not
specific. Apart from the peptide sequence, the other
components of the small molecule also influence its se-
lectivity. This is evident in [63] where screening of pep-
tide acyloxymethyl ketones (AOMK) inhibitors resulted
in the identification of TETD as the preferred peptide
sequence for Casp6 over Caspase-3 [41]. Yet, in the
same study, they found that Cy5 labeled VEID-AOMK
was a better substrate for Casp6 than the TETD version.
Similarly, chemical warheads can affect the selectivity of
inhibitors bearing the same peptide sequence. In fact,
VEID-CHO was more selective for Casp6 than −3 com-
pared to the fluoromethyl ketone (FMK) counterpart
[64]. Exosites also modulate substrate binding [65]. It is
possible that exosites are responsible for limiting the
cleavage of lamin A at the VEID sequence to Casp6 [62].
In our study, we find Z-VEID vinyl methyl sulfone inhib-
itors are 10-fold more selective against Casp6 than
Caspase-3 (Table 1: IC50). It is possible that interactions
of the lipophilic moiety or the chemical warhead with
natural substrate exosites increase selectivity of the
NWL inhibitors further towards Casp6.
Our results demonstrate that the NWL vinyl sulfone
caspase inhibitors are non toxic to human neurons and
neuroprotective against serum deprivation or APP over-
expression. NWL inhibitors prevent serum-deprivation-
or APPWT-expression induced TubΔCasp6 and neuritic
degeneration in human neurons, as shown previously
with Z-VEID-fmk and Casp6 dominant negative inhibi-
tors [12]. Maintaining full-length α-tubulin is essential
to stabilize microtubules [66], and intact microtubules
are critical for neuronal function. Since active Casp6 or
TubΔCasp6 are increased in human AD and hypoxia-
induced ischemia [4, 10, 27], inhibition of Casp6 and
other caspases in these conditions may help maintain
neuronal function. Even if Casp6 has been implicated in
axonal degeneration of NGF-dependent neurons, recent
evidence suggests that Casp3 also participates in axonal
degeneration [15, 19–26, 67]. In our study, the possibil-
ity that NWL inhibitors are acting on Casp3 to protect
neurons was excluded because only Casp1 and Casp6
are co-activated in our cellular model [12, 68, 69], and
both NWL-117 and NWL-154 are more effective against
Casp6 than Casp1 and Casp3. Moreover, in AD brains,
active Casp6 is detected in the absence of Casp3 [6, 70].
Thus, although studies in mouse peripheral neuron cul-
tures implicate Casp3 to be an important regulator of
axonal degeneration, the pathways involved in human
CNS neurons seem to converge on Casp6. Nevertheless,
given the strong inhibition of initiator caspases by the
NWL vinyl sulfone caspase inhibitors, it is not possible
in these experiments to conclude that the effect ob-
served was uniquely due to Casp6. The ability of short-
term treatment with NWL-117 to reverse episodic
(See figure on previous page.)
Fig. 5 Acute NWL-117 administration reverses novel object recognition deficits in Casp6-overexpressing KI/Cre mice. a Experimental design for
the in vivo study highlighting the novel object recognition (NOR) tests and injections. b Percent touches of objects during the NOR task in WT/
WT and WT/Cre controls (n = 16), and Casp6-expressing KI/Cre (n = 9) mice prior to injections. Statistical analysis was performed by one-way ANOVA
(p < 0.0001). c Distance traveled, (d) percent time moving, and (e) number of cell entries of control (n = 16) and KI/Cre (n = 9) mice. Statistical analysis
was performed by unpaired two-tailed t test. No significant differences were found in C-E. f Percent touches of objects during the NOR task following
saline (n = 8) or 20 mg/Kg NWL-117 (n = 8) injections in control mice. Statistical analysis was performed by one-way ANOVA (p < 0.0001). g Percent
touches of objects during the NOR task in pre- and post-injections (n = 4) saline injections in KI/Cre mice. Statistical analysis was performed by repeated
measures ANOVA (p = 0.7661). h Percent touches of objects during the NOR task in pre- and post- (n = 5) 20 mg/Kg NWL-117 injections in KI/Cre mice.
Statistical analysis was performed by repeated measures ANOVA (p = 0.0860) with Bonferroni’s multiple comparison test (* p < 0.05). i Distance traveled,
(j) percent time moving, and (k) number of cell entries of control mice injected with saline (n = 8) or NWL-117 (n = 8) and KI/Cre injected with saline
(n = 4) or NWL-117 (n = 5). Statistical analysis was performed by two-way ANOVA for panels (i) to (k) and no significant differences were found. For
panels (a–k), data represent the mean ± SEM and post hoc analyzes were performed using Bonferroni’s multiple comparison test (*p < 0.05,
**p < 0.01, and ***p < 0.001) unless stated otherwise
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memory impairments in our mice suggests that Casp6-
mediated damage is reversible in aged mice. We did not
determine whether other caspases are activated down-
stream of Casp6 in our mouse model and it remains a
possibility that the inhibition of other caspases such as
Casp4, 8, 9, and 10 additionally contributed to the im-
provement of cognitive deficits mediated by the over-
expression of Casp6. Nevertheless, the development of
specific Casp6 inhibitors and assessment of target en-
gagement will help determine whether it is Casp6 inhib-
ition alone, a combination of Casp6 with other caspases
activated as a consequence of Casp6 activation in the
mice brains, or a non-caspase effect that is responsible
for the behavioural improvement. Most importantly, our
findings suggest that vinyl sulfone NWL caspase inhibitors
are permeable to the blood-brain barrier with concentra-
tions in the hippocampus reaching in vitro IC50 values.
Intra-carotid injections were used as a proof of principle
as it limits exposure to peripheral tissues and is the most
rapid path to the brain. Rapid exposure was necessary as
the LC/MS-MS method can only detect free NWL-117.
Pharmacokinetic and pharmacodynamic detailed analyses
should be conducted in order to determine dosing regi-
mens for chronic administration studies. Only one other
Casp6 inhibitor, ED11, was shown to be brain permeable
and have a significant effect against behavioral and cogni-
tive deficits in an Huntington’s mouse model [18]. ED11
was delivered by subcutaneous pump delivery of 4 mg/kg/
day for 28 days or more. In contrast, NWL-117 reversed
Casp6-induced memory deficits after only 2 intraperito-
neal injections of 20 mg/kg within 72 h in the Casp6
transgenic mouse. These results support delivery of the
NWL inhibitors to the brain and suggest that Casp6-
mediated functional impairment can be rapidly reversed.
Compared to ED11 [18], NWL have several advan-
tages. ED11 is a 24 amino acid peptide (GRKKRRQRRR
PPQSSEIVLDGTDN) containing part of the human im-
munodeficiency virus (HIV) TAT-peptide and huntingtin
protein sequences. The TAT-peptide confers permeability
to plasma membranes and the blood-brain barrier, while
the huntingtin sequence is used to target Casp6. NWL in-
hibitors have 1) lower molecular weight, 2) lower IC50
against VEID substrates, and 3) no activity enhancing ef-
fect on caspases compared to ED11. Lower molecular
weight is associated with several different parameters that
determine the oral bioavailability of compounds as well as
their production cost [71]. In addition, large peptides have
lower half-lives in the body due to extensive degradation
and clearance by the liver and kidneys. This often
leads to the use of parenteral routes of administration, like
injections for insulin, which subsequently leads to reduced
patient compliance. Thus, the development of small mole-
cules is often preferred. In addition, although the IC50
against mutant huntingtin cleavage determined by fluores-
cence resonance energy transfer (FRET) was 12.12 nM for
ED11, ED11 did not inhibit the cleavage of VEID-
aminoluciferin as potently (>10 μM). Like NWL inhibi-
tors, ED11 showed inhibition of other caspases, but the
IC50 of ED11 against all caspases on their preferred sub-
strates has not been determined. Therefore, it is not pos-
sible to compare the selectivity of ED11 to that of NWL.
Furthermore, ED11 showed a significant enhancement of
Caspase-5 activity on the FRET assay. Deregulated
Caspase-5 activation could perturb inflammasome signal-
ling [72]. No activation of caspases was observed with
NWL inhibitors. Finally, ED11 is a competitive reversible
inhibitor that gets cleaved by Casp6. Although it has not
been measured, the affinity of cleaved ED11 could be
lower than the parent compound. Thus, the efficacy of
ED11 will be reduced over time. In contrast, irreversible
NWL inhibitors can completely inhibit the target enzyme,
require less frequent dosing, and have better safety profiles
than reversible inhibitors [52]. In theory, both these cas-
pase inhibitors are in the early phases of development and
will need much improvement before being considered
for clinical use.
The underlying molecular mechanism(s) involved in
the restoration of cognitive function remain unclear.
(See figure on previous page.)
Fig. 6 Hippocampal levels of synaptic and glial markers are unchanged with NWL-117 treatment. a Levels of Casp6 p20p10 (Casp6p20p10), α-
tubulin-cleaved by Casp6 (TubΔCasp6), α-tubulin (Tubulin), and β-actin in hippocampal protein extracts WT/WT, WT/Cre, and KI/Cre mice treated
with saline or 20 mg/Kg NWL-117. b & c Immunohistochemistry of TubΔCasp6-stained hippocampi from KI/Cre mice treated with saline (b) or
NWL-117 (c). Arrowheads mark some positive immunoreactivity. d Quantification of positive immunostaining shown in panel (b) and (c). e Levels
of p97 and p97-cleaved by Casp6 (p97ΔCasp6) in hippocampal protein extracts of KI/Cre mice treated with saline (n = 3) or NWL-117 (n = 3). f
Quantification of the levels of p97ΔCasp6/p97 shown in panel (e). g & h Levels of synapsin in hippocampal extracts from KI/Cre mice treated with
saline (n = 3) or NWL-117 (n = 3) (g) and quantified in (h). i Levels of Synaptophysin in hippocampal protein extracts from WT/WT, WT/Cre, and KI/
Cre (Casp6 overexpressing) mice treated with saline or NWL-117. j–k Brightfield scans of KI/Cre-Saline (j) and NWL-117 (k) mice brains stained for
synaptophysin by immunohistochemistry and quantification (l). m & n Iba1-stained hippocampi from KI/Cre mice treated with saline (m) or NWL-
117 (n). Arrowheads mark some positive immunoreactivity. o Quantification of the area of positive immunostaining for Iba1 over the total area of
the tissue. p Levels of GFAP in hippocampal extracts from KI/Cre mice treated with saline (n = 3) or NWL-117 (n = 3). q Quantification of the levels
of GFAP/β-actin. For panels (d), (l), and (o), data represent the mean ± SEM for each group: Control-saline (n = 5), Control-NWL-117 (n = 5), KI/Cre-sa-
line (n = 5), and KI/Cre-NWL-117 (n = 4). Statistical analysis was performed by two-way ANOVA and no significant differences were found. For panels (f),
(h), and (q), data represent the mean ± SEM and statistical analysis was performed by unpaired two-tailed t test, no significant differences were found.
SO: Stratum Oriens, PCL: Pyramidal Cell layer, SR: Stratum Radiatum, SLM: Stratum Lacunosum
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NWL-117 had no effect on hippocampal levels of TubΔ-
Casp6 or p97ΔCasp6, synaptic protein expression, or
glial inflammation markers. Our inability to detect
changes may be a consequence of the short treatment
period. Furthermore, Casp6 expression and activation is
limited to the pyramidal neurons of the CA1 region of
the hippocampus and this does not provide sufficient
material to assess Casp6-cleaved protein substrates by
western blot, especially since neurons will not all degen-
erate at the same time. In addition, the rapid reversal of
cognitive deficits suggest that the effect is possibly medi-
ated through neuronal plasticity which re-establishes
neuronal function, therefore, different tools encompass-
ing synaptic plasticity need to be developed to assess
how NWL reverses cognitive deficits in these mice. In
other mice studies, cognitive amelioration was measured
in the absence of changes in synaptic protein expression
or brain volume [18, 73]. Future long-term prophylactic
treatment studies may enlighten us to the effects of
NWL-117 in the context of age and Casp6-dependent
cognitive impairment and allow proper identification of
target engagement. In addition, NWL inhibitors need to
be administered to different AD mouse models which
display an aggravated pathological phenotype, such as
high Aβ load or NFTs, to determine the efficacy of this
treatment in re-establishing memory function in other
models of neurodegeneration.
NWL inhibitors have advantages over current research
tools as they are permeable to the blood brain barrier
and are less toxic than the commercially available fluor-
omethylketone based tools (cell permeable inhibitors
and FLICA reagents) without any compromise in select-
ivity. As NWL Inc. improves on their small molecules
Casp6 inhibitors, experiments on non-human primates,
clinical trials, and the development of radio-ligands for
positron emission tomography will become reality.
Conclusion
This study reveals the potential for vinyl sulfone cas-
pase inhibitors to effectively inhibit Casp6 activity and
promote neuronal axonal integrity. Also, our results
suggest that Casp6-mediated damage can be reversed
in aged brains. Much work still needs to be done to
confirm target engagement, measure selectivity, po-
tency, and blood-brain-barrier permeability in animal
models. However, with the increasing number of re-
search groups focusing on Casp6 as a therapeutic target
against neurodegenerative diseases, the possibility that
Casp6 inhibitors will one day reach human trials is
promising. Whether Casp6 inhibitors will be sufficient
as a monotherapy, or whether they will become part of
a combinatorial approach with Tau, amyloid, and other
emerging therapies is a question that will be answered
in the years to come.
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